{"id":"qlm3004-concentration-2","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108774","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of QLM3004 Concentration 2 is not well understood, but it is believed to work by binding to the molecular target, which leads to a cascade of downstream effects that ultimately result in the therapeutic effect.","oneSentence":"QLM3004 Concentration 2 is a drug that targets the molecular target to exert its therapeutic effect.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:30:51.258Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06151587","phase":"PHASE3","title":"A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-08-20","conditions":"Myopia","enrollment":735}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3923,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"QLM3004 Concentration 2","genericName":"QLM3004 Concentration 2","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}